Home › Compound Library › NuvaRing (Etonogestrel / EE Vaginal Ring)

NuvaRing (Etonogestrel / EE Vaginal Ring)

Hormonal Contraceptiveprescriptiontransdermal patch · inferred

Vaginal ring releasing 120 mcg etonogestrel + 15 mcg ethinyl estradiol daily for 3 weeks, then 1 week off. Avoids first-pass hepatic metabolism. More stable hormone levels than oral pills. Etonogestrel t1/2 ~29h after removal.

Projected serum levels — 1 ring (≈ 14.7 mg), custom (shown daily)

NuvaRing (Etonogestrel / EE Vaginal Ring)
NuvaRing (Etonogestrel / EE Vaginal Ring) modeled serum levels, 1 ring (≈ 14.7 mg) custom (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 14 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 14
NuvaRing (Etonogestrel / EE Vaginal Ring) modeled serum levels with a loading dose of 3 ring, then 1 ring (≈ 14.7 mg) custom (shown daily) The first dose is larger so levels approach steady state faster. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 1 ring (≈ 14.7 mg) custom (shown daily) (transdermal patch).

Loading schedule: 3 ring on day 1, then 1 ring (≈ 14.7 mg) custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~14 days: peak ≈ 1.2 mg, trough ≈ 1.2 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormonal Contraceptive
Route modeled
Transdermal patch
Model confidence
inferred
Half-life
29 h
Common dose
1 ring (≈ 14.7 mg)
Suggested maximum
1 ring/day
Reference dose range
0.50–1 ring (single dose)
Suggested cadence
custom (shown daily)
Validated against
14.7 mg td — Cmax 0.002 mg/L at 168 h

Documented interactions

  • contraindicated
    Clarithromycin (Biaxin) + NuvaRing (Etonogestrel / EE Vaginal Ring) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change NuvaRing (Etonogestrel / EE Vaginal Ring) AUC by ~5.14x

  • contraindicated
    Diltiazem + NuvaRing (Etonogestrel / EE Vaginal Ring) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change NuvaRing (Etonogestrel / EE Vaginal Ring) AUC by ~5.14x

  • contraindicated
    Efavirenz (Sustiva) + NuvaRing (Etonogestrel / EE Vaginal Ring) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change NuvaRing (Etonogestrel / EE Vaginal Ring) AUC by ~0.14x

  • contraindicated
    Grapefruit (whole fruit) + NuvaRing (Etonogestrel / EE Vaginal Ring) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change NuvaRing (Etonogestrel / EE Vaginal Ring) AUC by ~5.14x

  • contraindicated
    Grapefruit Juice + NuvaRing (Etonogestrel / EE Vaginal Ring) CYP inhibition

    Grapefruit Juice mechanism_based of CYP3A4 predicted to change NuvaRing (Etonogestrel / EE Vaginal Ring) AUC by ~5.14x

  • contraindicated
    Paxlovid (Nirmatrelvir/Ritonavir) + NuvaRing (Etonogestrel / EE Vaginal Ring) CYP inhibition

    Paxlovid (Nirmatrelvir/Ritonavir) mechanism_based of CYP3A4 predicted to change NuvaRing (Etonogestrel / EE Vaginal Ring) AUC by ~5.14x

Serum checks 260 modeled interaction pairings for nuvaring (etonogestrel / ee vaginal ring) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics of a Combined Contraceptive Vaginal Ring Timmer CJ, Mulders TM · Clinical Pharmacokinetics, 2000 DOI

    PK study showing NuvaRing provides steady etonogestrel and EE levels with 2-3x less peak-trough fluctuation than oral contraceptives.

  2. Efficacy, Cycle Control, and User Acceptability of a Novel Combined Contraceptive Vaginal Ring Oddsson K et al. · Obstetrics & Gynecology, 2005 DOI

    Large RCT showing NuvaRing efficacy comparable to oral OCs with superior cycle control (less breakthrough bleeding) and high user satisfaction.

  3. Venous Thrombosis in Users of Non-Oral Hormonal Contraception Lidegaard O et al. · BMJ, 2012 DOI

    Large Danish cohort study finding vaginal ring carries similar VTE risk to drospirenone OCs (~6.5 per 10,000 woman-years).

3 published studies referenced in the app, each with a plain-language summary.